Merck releases study of Vioxx substitute, Arcoxia

10/20/2004 | Forbes

Merck released the results of a new study on its pain reliever Arcoxia, intended as a substitute for its troubled Vioxx, and concluded it was gentler on the stomach than its predecessors. But the study did not address the problem that led to Vioxx being removed from the market -- that it caused heart problems. The Arcoxia study was conducted over a nine-month period, and the Vioxx tie to heart problems occurred at least 18 months into its trials. Analysts do not expect FDA approval for Arcoxia without further safety studies.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI